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1. Introduction 
Age related macular degeneration (AMD) is the leading cause of blindness in the developed 
countries. Approximately 8 million people in America have AMD and the number of 
advanced AMD is likely to rise by 50% by year 2020 due to the projected increase in the 
number of elderly people (Friedman et al., 2004). AMD is a condition of significant 
morbidity in terms of both physical and mental health (Hassell et al 2006). The burden of 
this disease is multifaceted as both the individual and society bear a cost. The individual has 
a loss of independence and ability of self care, with a pressure on society to fulfil the need 
for community and vision related support.  
In this review of AMD, we will explore the epidemiology of AMD, the criteria for diagnosis 
with particular focus on the pathophysiology and treatments of wet AMD. 
1.1 Epidemiology 
AMD affects a large proportion of the elderly population. By applying the criteria of 
presence of macular drusen greater than 63 micrometres in diameter on fundus 
photography, up to 61% of adults over 60 years have some degree of AMD (Piermarocchi et 
al 2011). With a high estimated prevalence, it is important to understand the potential risk 
factors for this condition. 
A meta analysis of published data suggests that increasing age, current cigarette smoking, 
previous cataract surgery, and a family history of AMD show strong and consistent 
associations with late AMD. Risk factors with moderate and consistent associations were 
higher body mass index, history of cardiovascular disease, hypertension, and higher plasma 
fibrinogen. Risk factors with weaker and inconsistent associations were gender, ethnicity, 
diabetes, iris colour, history of cerebrovascular disease, and serum total and HDL 
cholesterol and triglyceride levels (Chakravarthy et al 2010).  
Direct associations between AMD and age, cataract, family history, alcohol consumption, 
the apolipoproteins A1 and B were also found in a 14 year follow up amongst a city 
populations (Buch et al 2005). In addition, recent data on human genome project have linked 
a complement H polymorphism Try402His on chromosome 1 to increased risk of AMD 
(Klein et al.,2005). Ala69ser polymorphism in the ARMS2 gene on chromosome 10 is yet 
another instance where genetic susceptibility for this condition has been established (Rivera 
et al., 2005). It has also been shown that ARMS2 polymorphism together with smoking, can 
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synergistically increase the risk of developing AMD (Schmidt et al., 2006). Therefore it is 
evident that AMD is a result of interplay of genetic and environmental factors leading to the 
final pathology. 
Better understanding of risk factors can help to identify individuals at high risk for wet 
AMD who may benefit from early intervention with existing or novel therapies. Using 
visual acuity as an outcome measure, visual prognosis is more favourable in patients with 
early intervention (Wong et al 2008). 
1.2 Classification of AMD and diagnosis 
AMD is characterized by the deposition of polymorphous material between the retinal 
pigmented epithelium and Bruch’s membrane (Jager et al., 2008). These depositions are 
named Drusen. Drusen are categorised by sizes as, small(<63μm), medium (63-124 μm) and 
large (>124μm) (Bird et al., 1995). They are also considered as hard or soft depending on the 
appearance of their margins on opthalmological examination. While hard drusens have 
clearly defined margins, soft ones have less defined and fluid margins (Bird et al., 1995). 
Classically the condition is divided in to two main subtypes; dry/non exudative and 
wet/exudative. The Age-related Eye Disease Study (AREDS) fundus photographic severity 
scale is one of the main classification systems used for this condition (Sallo et al 2009): 
No AMD (AREDS category 1) 
No or a few small (<63 micrometres in diameter) drusen. 
Early AMD (AREDS category 2)  
Many small drusen or a few intermediate-sized (63-124 micrometres in diameter) drusen, or 
macular pigmentary changes. 
Intermediate AMD (AREDS category 3)  
Extensive intermediate drusen or at least one large (≥125 micrometres) drusen, or 
geographic atrophy not involving the foveal centre. 
Advanced AMD (AREDS category 4) 
Geographic atrophy involving the foveal centre (atrophic, or dry AMD)  
Choroidal neovascularisation (wet AMD) or evidence for neovascular maculopathy 
(subretinal haemorrhage, serous retinal or retinal pigment epithelium detachments, lipid 
exudates, or fibrovascular scar). 
Wet AMD results from the abnormal growth of blood vessels from the choriocapillaris 
(choroidal neovascularisation), through Bruch's membrane. The fragility of the blood vessels 
and inflammatory processes lead to subretinal haemorrhages and fibrovascular scarring. 
This process can occur de novo or as a progression of dry AMD.  
As with many classification systems, there is variability in AMD grading between clinicians. 
Therefore although such scales are important for accurate follow up of AMD progression, 
care is needed in their interpretation. 
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To classify AMD, multiple ophthalmological tools have proven to be useful including dilated 
indirect ophthalmoscopy, stereoscopic fundus photography, amsler grid testing, fundus 
fluorescein angiography (FFA) and optical coherence tomography (OCT). Of the mentioned 
techniques available, FFA is of great importance as it allows differentiation between 
neovascularisation attributable to AMD and that caused by other conditions. The use of FFA 
has enabled sub-classification of wet AMD according to the appearance of the lesions and the 
location of choroidal neovascularisation in relation to the fovea. The appearance can be 
described as classic or occult, which is according to the defined features of the membrane at 
early and late phases. The location can be extrafoveal (choroidal neovascularisation greater 
than 200um from the foveal avascular zone), juxtafoveal (choriodal neovascularisation is closer 
than 200um from the fovealavascualr zone) and sub-foveal (originating or extension of 
choroidal neovascularisation to the centre of the avascular zone). OCT provides a cross 
sectional image of the macula and identifies retinal pigment detachment, fluid accumulation 
and vitero-macular attachments. OCT has become an important tool in the monitoring 
progression of wet AMD especially in light of new therapeutic possibilities. 
2. Pathophysiology of wet AMD 
In this section we will explore the clinical presentation and the current pathophysiological 
mechanism underlying the development of AMD. 
2.1 Clinical presentation of wet AMD 
Clinically, AMD presents with visual loss of varying severity. Early in the course of disease, 
patients can present with very mild symptoms or be completely asymptomatic. Some patients, 
however, do experience a loss of contrast sensitivity, blurred vision and scotomas as the 
disease progresses to the intermediate stage (Jager et al., 2008). Other visual abnormalities 
associated with AMD include metamophopsia(distortion of straight lines), disparity of image 
size, macropisa and micropsia, hyperopic refractive shift with associated anisometriopia, light 
glare, floaters, photopsia (Schmidt-Erfurth et al 2004). However, neovascular or wet AMD, 
unlike the dry subtype, can have a sudden onset of presentation due to subretinal 
haemorrhages and exudates leading to retinal detachment and a acute visual loss (Jager et al., 
2008). Although wet AMD is only responsible for 15% of the total AMD, it is responsible for 
more than 80% of AMD-related severe visual loss and blindness (Fine et al., 1986). 
2.2 Pathophysiological models for AMD development 
Various theories and models have been proposed to explain the pathophysiology of AMD 
with multiple factors contributing to the final outcome. Most models proposed focus either 
on the Bruch’s membrane or on the retinal pigmented cells overlying this membrane.  
Retinal pigment epithelial (RPE) cells, form a single layer of cells overlying Bruch's 
membrane with photoreceptors located anterior to RPE layer. RPE cells play a very complex 
role in preserving photoreceptors and their function. One of their major functions is to 
remove the shed outer segments of the photoreceptors by phagocytosis (Chang and 
Finnemann, 2007;Finnemann and Silverstein, 2001). It has been shown that failure of this 
process will result in build up of debris between the retinal layer and the Bruch’s membrane 
leading to retinal degeneration (Nandrot et al., 2004).  
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Fig. 1. Fundoscopic view- dry AMD. Note there is no neovascularisation evident. 
 
Fig. 2. Fundoscopic view of wet AMD. Excessive neovascularisation in macular region. 
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Fig. 3. Fundus fluorescein angiography (FFA) image of corresponding eye affected by wet 
AMD. 
 
Fig. 4. Optical coherence tomography (OCT) image of corresponding eye. Significant 
macular oedema is evident. 
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In AMD, various abnormalities in the Bruch’s membrane have been shown to lead to the 
disruption of RPE function (Sun et al., 2007), and this in turn can lead to the disruption of 
photoreceptor function and their loss. Therefore, Bruch's membrane has been the focus of 
great deal of AMD research.  
To understand the pathophysiology of AMD, it is necessary to understand the basic normal 
structure of Bruch’s membrane. Bruch’s membrane is a penta-laminar structure, composed 
of RPE basement membrane, inner collagenous layer, elastin lamina, outer collagenous layer 
and choriocapillary basement membrane (Zarbin et al 2003). Each layer has a different 
composition of extracellular ligands, capable of interacting with integrins on the RPE cells. 
The top layer of Bruch's membrane (the RPE basement membrane) is of great importance as 
it contains an important extracellular matrix called laminin (Das et al., 1990; Zarbin,2003; 
Pauleikhoff et al., 1990) necessary for RPE adhesion and attachment. 
Over the years, molecular analysis of Bruch's membrane has lead to the identification of 
composition of each layer as summarized in the table below (Das et al., 1990; Zarbin, 2003; 
Pauleikhoff et al., 1990).  
 
Layer 1. Basement membrane 
(Immediately underneath RPE layer) 
Collagen IV, Collagen V, laminin, Heparan 
sulphate
Layer 2. Inner collagenous layer 
Collagen I, Collagen III, Collagen V, 
fibronectin, Chondroitin sulphate, 
dermatan sulphate
Layer 3. Elastic lamina Elastin, Collagen I, Fibronectin 
Layer 4. Outer collagenous layer 
Collagen I, Collagen III, Collagen V, 
fibronectin, Chondroitin sulphate, 
Dermatan sulphate
Layer 5. Choriocapillaries basement 
membrane 
Collagen IV, Collagen V, Collagen VI, 
laminin, heparan sulphate
Table 1. Matrix components of different layers of Bruch's membrane.  
Each layer of Bruch's membrane is composed of mixture of proteoglycans and adhesive 
ligands. Adhesive ligands interact with integrins on the surface of RPE cells. Different 
subunits of integrins interact with different class of ligands. RPE cells attachment to Bruch's 
membrane is largely dependent on integrin's ability to anchor the cell to the membrane 
firmly. Pathological states affecting the membrane or RPE cells therefore, may disrupt this 
important interaction leading to loss of adhesion and death of RPE cells. 
A large number of hypotheses have existed regarding pathological processes involved in AMD. 
Overall, the pathological mechanisms proposed in AMD can be divided into 4 categories of 
inflammation, oxidative stress, abnormal ECM production, formation of CNVs and 
neovascularisation (Zarbin, 2004). These various components can happen either sequentially or 
they can occur simultaneously, leading to the final outcome seen in AMD (Zarbin, 2004). 
2.2.1 The inflammation component 
Although drusen formation is one of the hallmarks of AMD, controversy exists as to 
whether they are directly involved in the pathology of AMD. Drusen can be found in non-
AMD patient eyes incidentally associated with aging (Zarbin, 2004). However, others have 
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suggested that the accumulation of large numbers of macular drusen is a necessity for the 
development of geographic atrophy and choroidal neovascularization characteristic of 
advanced AMD (Harman, 1956; Wallace, 1999). 
Biochemical and immunohistological studies suggest drusen consist of immunoglobulins 
and components of the complement pathway (such as the C5b-C9 complex), acute phase 
response proteins raised in inflammation (CRP, amyloid P component and alpha1-
antitrypsin), proteins that modulate the immune response (such as vitronectin, clusterin, 
apolipoprotein E, membrane cofactor protein and complement receptor1), major 
histocompatibility complex class 2 antigens, and HLA-DR and cluster differentiation 
antigens (Hageman et al., 1999; Johnson et al., 2000; Mullins et al.,2000; Sakaguchi et al., 
2002; Zarbin, 2004). In addition, there are cellular components in drusen including RPE 
membrane debris, lipofuscin, melanin and choroidal dendritic cells (Ishibashi et al., 1986; 
Killingsworth, 1987; Mullins et al., 2000). 
In support of this inflammatory theory, intravitreal injections of corticosteroids reduce the 
incidence of laser-induced CNVs in non human primates, possibly by reducing 
inflammation (Ishibashi et al., 1985). 
2.2.2 Oxidative stress 
It has been shown that with increasing age, oxidative damage in RPE cells also increases 
(Wallace et al., 1998). This is associated with a decrease in levels of antioxidant protective 
agents such as plasma glutathione, while oxidized glutathione levels increase. Also 
antioxidant vitamins, such as vitamin C and E, show a decline with increasing age (Rikans 
and Moore, 1988; Vandewoude and Vandewoude, 1987). 
In support of oxidation stress as one of the factors involved, accumulation of lipofuscin has 
been observed in aging eyes. Lipofuscins are derivatives of vitamin A metabolites (Katz et 
al., 1994). It has been shown that in the first decade of life, they only constitute 1% of the 
cytoplasmic volume of RPE cells where as this is increased to 19% of cytoplasmic volume in 
the elderly (De La Paz and Anderson, 1992; Feeney-Burns et al., 1984). 
In vitro studies suggest that RPE lipofuscin is a photo-inducible generator of reactive oxygen 
species. Lipofuscin granules are continuously exposed to visible light and to high oxygen 
tension, which causes the production of reactive oxygen species and oxidative damage to 
RPE cells (Wassell et al., 1999; Winkler et al.,1999; Zarbin, 2004). 
RPE lipofuscin accumulation can ultimately lead to the disruption of lysosomal integrity, 
induce lipid peroxidation, reduce the phagocytic capacity of RPE cells and ultimately lead to 
loss of RPE cells (Boulton et al., 1993; De La Paz and Anderson, 1992; Sundelin and Nilsson, 
2001; Zarbin, 2004). 
Consistent with the oxidative stress model, clinical studies on the use of antioxidants has 
shown that in patients with extensive intermediate drusen, supplementation with 
antioxidant vitamins and minerals reduces the risk of developing advanced AMD from 28% 
to 20% (Age related eye disease study research group, 2001). 
2.2.3 Abnormal ECM production 
With aging, various changes can happen to the extracellular matrix deposited within the 
Bruch’s membrane. It has been shown that there is a decline of laminin, fibronectin and type 
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IV collagen in the aging RPE basement membrane, particularly over the drusen (Pauleikhoff 
et al., 1999). 
There is an age dependent increase in type I collagen within the Bruch’s membrane, with an 
increase in the thickness of the membrane from 2 micrometres at birth, to up to 6 
micrometres in the elderly ages (Ramrattan et al., 1994). During aging , the membrane 
glycosaminglycans in Bruch’s membrane increase in size, and there is an increase in the 
heparan sulphate proteoglycan content of the membrane (Hewitt et al., 1989). Furthermore, 
glycation end products can accumulate within the Bruch’s membrane with aging, trapping 
other macromolecules (King and Brownlee, 1996; Schmidt et al., 2000). 
RPE cells themselves are the source of many of these ECM molecules. Histologically, 
abnormal extracellular matrix can be found between the RPE cells and the basement 
membrane (basal laminar deposits) and external to the basement membrane within the 
collagenous layers of the membrane (basal linear deposits) (Bressler et al., 1994; Green and 
Enger, 2005). Drusen therefore can be a localized accentuation of these deposits in AMD 
(Bressler et al., 1994). 
The increase in thickness and change in composition of the Bruch’s membrane in AMD can 
lead to a disruption of the exchange of molecules between choriocapillaris and the 
subretinal space (Starita et al., 1997). 
In support of this model, it has been shown that the hydraulic conductivity of the Bruch’s 
membrane falls exponentially with age. Measurements have shown that most of the 
resistance to water flow lies in the inner collagenous layer of the Bruch’s membrane which is 
possibly due to accumulation of abnormal entrapped material within this plane (Starita et 
al., 1997). Therefore, the thickened Bruch’s membrane in AMD may lead to a diffusion 
barrier, leading to RPE and retinal dysfunction (Pauleikhoff et al., 1999; Remulla et al., 1995). 
2.2.4 CNV formation  
Multiple factors have been proposed as promoters of new blood vessels formation in wet 
AMD. Changes in the ECM is one of the abnormalities seen in AMD which can lead to the 
formation of new blood vessels. The mechanism by which this phenomenon occurs is not 
completely understood but is likely to be a multifactorial. The risk of CNV in AMD 
increases with the increase in Drusen. Some drusen components and advanced glycation 
end products stimulate the production of angiogenic factors (Lu et al., 1998; Mousa et al., 
1999). The increased thickness of Bruch’s membrane can also lead to reductions in 
choriocapillary blood flow and hypoxia (Remulla et al., 1995). Hypoxia in turn can 
upregulate genes Ang-1 and Ang-2, with Ang-1 promoting maturation and stabilization of 
blood vessels, and Ang-2 conferring endothelial cell responsiveness to angiogenic factors 
(Hanahan, 1997; Maisonpierre et al.,1997). In addition, RPE cells are themselves known to 
produce angiogenic factors, such as VEGF, (Kim et al., 1999) which can lead to 
neovascularisation. High concentrations of VEGF and its receptors are found in CNV and 
RPE cells (Kliffen et al., 1997; Kvanta et al., 1996). Furthermore, anti-VEGF treatments 
prevent laser induced CNV formation in primate models of AMD (Krzystolik et al., 2002). 
It has been shown that overexpression of VEGF in transgenic mice leads to the formation of 
aberrant choriocapillaries. However, these vessels are not capable of penetrating the intact 
Bruch’s membrane (Schwesinger et al., 2001). Therefore, damage to Bruch’s membrane due 
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to various factors in combination with the upregulation of VEGF, can synergistically lead to 
the choriocapillary CNVs penetrating the membrane and reaching the subretinal space 
(Schwesinger et al.,2001; Zarbin ,2004). 
One of the molecules that has been studied extensively in our lab is a glycoprotein called 
tenascin C, known to be overexpressed in angiogenesis (Zagzag and Capo, 2002; Zagzaget 
al., 1996), neovascularisation and wound healing (Maseruka et al., 1997). Tenascin C 
deposition can occur in the Bruch’s membrane in wet AMD on the basal side of RPE cells 
(Fasler-Kan et al., 2005) and in association with CNVs in the pathological Bruch’s membrane 
(Nicolo et al., 2000). Tenascin C has been shown to prevent adhesion of RPE cells to 
extracellular matrix (Afshari et al 2010). Therefore accumulation of this molecule associated 
with CNV formation may play an important role in RPE loss from the Bruch's membrane 
seen in AMD (Afshari et al 2010).  
In summary, different pathological processes during aging and in AMD can lead to 
modifications in the Bruch’s membrane which ultimately becomes a less supportive 
environment for the RPE adhesion and function. 
3. Experimental models available for studying wet AMD  
3.1 In vitro and ex vivo models - Advantages vs disadvantages 
In vitro models have allowed development of simplified systems to study processes 
involved in wet AMD. Most in vitro models have focused on the role of angiogenesis and 
isolation of Bruch’s membrane to assess adhesion and survival of RPE cells.  
Tezel and Del priore first described methodology for accessing different layers of Bruch’s 
membrane to allow in vitro assessment of RPE adhesion at different levels of Bruch’s 
membrane. A combination of enzymatic treatment and mechanical techniques were used to 
expose each layer sequentially starting from the top basal lamina and moving to deeper 
structures. Using this technique, it was shown that deeper layers of Bruch’s membrane are 
less supportive of RPE attachment (Del priore et al 1998; Tezel TH 1999 FEB; Tezel TH 1999 
March). RPE cell adhesion to Bruch’s membrane may play a detrimental role both in AMD 
and following RPE transplantation. 
An alternative way of accessing Bruch’s membrane used in our lab is the water lysis 
technique (Afshari et al 2010). In this method, eye globes are dissected out and separated 
from their muscle attachments. The anterior chamber is then dissected away leaving the 
posterior chamber and retina and Bruch’s-choroid-sclera. Retinal layer is then carefully 
removed leaving the Bruch’s-choroid-sclera trilaminar structure which can be subsequently 
exposed to water. Exposure to water leads to lysis of endogenous RPE cells. Lysed RPE cells 
are then flushed away from the surface of Bruch’s membrane using a mini water jet. This 
procedure therefore results in formation of a denuded Bruch’s membrane which can allow 
further experiments such as transplanting exogenous RPE cells to assess adhesion and 
migration of the transplanted cells (Afshari et al 2010). The advantages of this technique is 
that minimal treatment of the tissue is required with preservation of natural Bruch’s 
membrane. In addition the preparation of the Bruch’s membrane for adhesion and 
migration assay is a short procedure. Immunostaining of both frozen sections and electron 
microscopy of the membranes following water treatment have confirmed complete removal 
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of endogenous RPE layer therefore creating a suitable environment for transplanting 
exogenous cells (Afshari et al 2010). However for assessment of adhesion on different layers 
such as deeper collagen layers of Bruch’s membrane, methodology by Tezel and Del priore 
et al can be used (Del priore et al 1998; Tezel TH 1999 FEB; Tezel TH 1999 March). 
Although much has been learned from the use of eyes derived from experimental animals 
such as rats and rabbits, a major problem faced is the unique human age related changes 
and AMD related pathological processes that have been hard to recapitulate in animal 
models. Therefore recent attention has been on use of human derived Bruch’s membrane 
and ex vivo models whereby pathological or normal samples can be used from donors. A 
great advantage of this technique is that good methodology exists for isolation of layers of 
Bruch’s membrane, and eyes from various stages of the disease can be studied. A 
disadvantage of using human samples is the difficulty in obtaining high quality tissue 
before post mortem deterioration occurs. 
3.2 In vivo models - Advantages vs disadvantages 
In vivo animal models have been used widely in studying AMD. Creating animal models 
specific for AMD has been a difficult task to achieve. One of the older animal models used in 
AMD research is Royal College of Surgeons rats (RCS rats) where RPE cells are gradually 
lost over time along with photoreceptors. RCS rats have been used in RPE transplantation 
experiments widely to assess efficiency of transplanted cells in replacing the lost 
endogenous RPE cells and preventing photoreceptor loss (Li and Turner 1988). However 
these rats are a better model for studying retinitis pigmentosa and therefore may differ 
considerably with regards to pathology from AMD.  
Another used animal model comprises of mechanically scratching the RPE layer. This allows 
creation of focal areas devoid of RPE cells allowing studying various transplantation or 
pharmacological treatments. Rabbits are used generally in this model (Philips 2003) due to 
bigger size of the eye globes allowing easier access. 
None of the models above recapitulate the neovascularisation seen in wet AMD. However 
recently more models have emerged which reproduce the neovascularisation process. Some 
of these models use growth factors such as b-fibroblast growth factor (FGF) or vascular 
endothelial growth factor (VEGF) to induce the endothelial cells proliferation and migration 
to promote CNV formation in rats, rabbits and monkeys (Montezumas.R 2009, Edwards A. 
2007, Lassota N 2008, Baba T 2010). Over the years different techniques have been used to 
deliver growth factors ranging from direct injections, lentiviral vectors, cells secreting 
growth factors or transgenic animals secreting the VEGF (Spilsbury 2000; julien 2008; 
Okamoto et al1997; Cui et al 2000) . 
Newer techniques which can stimulate CNV formation include injection of matrigel 
subretinally which allows a suitable environment for blood vessels to grow into (Cao J 2010). 
An alternative to this has been use of polyethylene glycol injections subretinally which leads 
to activation of complement cascade and generation of VEGF leading to CNV formation in 
mouse (Lyzogubov et al 2011).  
Multiple transgenic mice lines also have been created which produce CNV through different 
methods. One of such animal models is use of transgenic mice producing mitogen 
prokineticin 1 (Hpk1) which specifically stimulates fenestrated endothelial cells. 
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Introduction of this mitogen can lead to CNV formation from choriocapillaries (Tanaka N 
2006). By generating transgenic mice expressing Hpk1 in retina, Tanaka et al were able to 
show that Hpk1 promotes development of CNV with no effect on retinal vasculature. 
Interestingly, these mice also show increased levels of lipofuscin which is also seen in AMD 
(Tanaka N 2006).  
One of the most interesting examples of transgenic mice used in studying wet AMD is the 
ccr2/ccl2 transgenic mice which are unable to recruit macrophages to RPE layer and Bruch’s 
membrane. This leads to accumulation of C5a and Immunoglobulin G which in turn leads to 
stimulation of VEGF production (Ambati 2003; Takeda et al. 2009). 
An alternative method of CNV formation is application of laser to generate a focal area of 
burn within the Bruch's membrane which in turn leads to CNV formation. This technique 
over the years has become one of the most standard and widely used techniques in studying 
wet AMD. Various laser treatments using krypton, argon and diode have all been able to 
induce CNV formation in mice, rats, pigs and monkeys (Dobi et al 1989; Frank et al 
1989;Ryan et al. 1979; Saishin et al 2003). To initiate CNV formation using laser, it is 
necessary for RPE layer, Bruch’s membrane and the underlying choroid to be damaged by 
the laser to allow penetration and initiation of new blood vessel formation. The laser 
induced CNV formation is VEGF mediated, as different methods of blocking VEGF using 
peptides and antibodies in mice, rats and monkeys are all able to block the 
neovascularisation process (Hua J 2010; Goody RJ 2011). 
4. Treatments available for AMD and their mode of action 
4.1 Surgical and cellular transplantation/replacement 
Since defects in Bruch’s membrane in age related macular degeneration leads to RPE loss, 
replacement of RPE cells by transplantation has been proposed as a technique to prevent 
secondary photoreceptor death. In the past two decades, studies in various animal models 
of retinal degeneration and RPE loss have shown that RPE cell replacement may be a 
feasible technique to prevent a secondary photoreceptor loss due to RPE damage (Lund et 
al., 2001). 
Li et al in 1988 demonstrated that RPE transplantation in young neonatal and adult rats 
allows a repopulation of denuded areas on the Bruch’s membrane and prevent the 
photoreceptor degeneration in dystrophic RCS rat models of AMD (Liand Turner, 1988a, b). 
In separate studies, Castillo et al have shown that transplantation of adult young human 
RPE cells derived from cadaveric eye samples, into the dystrophic RCS rats can salvage the 
photoreceptor loss in this model (Castillo et al., 1997). 
Furthermore, subretinal transplantation of the RPE cell line ARPE-19, the most widely used 
adult human RPE cell line, in dystrophic RCS rats can rescue the photoreceptors (Wang et 
al., 2005). Other animal models, such as rabbit models of RPE damage, showed that 
mechanical debridement of the Bruch’s membrane followed by autologous RPE 
transplantation leads to the repopulation of debrided Bruch’s membrane with preservation 
of photoreceptors (Phillips et al., 2003). 
In humans patients with AMD, the formation of choroidal new vessels is part of the 
pathology of advanced wet AMD. The removal of CNVs has also been carried out in human 
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patients with AMD. This can be followed by autologous transplantation of RPE cells, either 
harvested from the periphery of the Bruch’s membrane which is not affected by the disease 
process (Binder et al., 2007), or from RPE cells from other donors (Algvere et al.,1994). 
Algevere et al at in 1994 assessed the effect of human fetal RPE transplantation in 5 patients 
with AMD after the removal of CNVs. Human fetal RPE cells survived up to 3 months and 
covered the denuded areas of the Bruch’s membrane (Algvere et al., 1994). 
Other studies have also assessed the effect of adult autologous transplantation of RPE cells 
in AMD. It has been shown that autolgous transplantation following the removal of CNVs is 
a feasible technique and associated with some visual acuity improvement (Binder et al., 
2004). 
In 2007 Maclaren et al carried out autologous transplantation of the RPE cells, following 
submacular CNV excision, and reported viable grafts at 6 months time point and some level 
of visual function improvement in some patients. However, the complications associated 
with the surgery remained high (MacLaren et al., 2007). 
RPE transplantation has traditionally been carried out as cell suspension but, due to 
problems with RPE attachment to Bruch's membrane, more recently RPE-choroid sheets 
have been tried as a means of delivering RPE cells (Treumer et al 2007). In 2011, Falkner-
Radler et al, carried out a study comparing RPE cell suspension with that of RPE-choroid 
sheet transplantation. This study showed that anatomical and functional outcome in both 
cases were comparable with no significant difference between the two techniques in humans 
(Falkner-RadlerCl 2011). 
Despite some improvements gained in the visual function, the results from the CNV 
removal combined with RPE transplantation, have not been as successful as those observed 
with animal models. This may be due to age related changes specific to human AMD which 
are absent in the animal models used in studying AMD and RPE transplantation. 
RPE transplantation as a therapeutic technique faces major limitations, including poor 
adhesion of RPE cells when transplanted subretinally. Studies have shown that RPE cells 
require rapid adhesion to avoid apoptosis (Tezel and Del Priore, 1997,1999). Therefore, there 
is a limited time period after subretinal injection during which RPE cells need to reattach 
before undergoing cell death. 
The lack of adhesion following transplantation is likely to be multifactorial due to the 
molecular changes resulting from pathological age related changes in the membrane, and 
other changes contributed by the disturbance of normal architecture of the membrane from 
the surgery. 
Various studies using ex vivo models have demonstrated major differences between RPE and 
Bruch's membrane in patients from different ages, emphasizing the important role of aging 
in the pathological process. Studies by Gullapalli et al have shown that aged submacular 
human Bruch’s membrane does not support adhesion, survival and differentiation of fetal 
RPE cells effectively (Gullapalli et al., 2005). Multiple studies have shown that RPE cell 
adhesion to the Bruch’s membrane is reduced on aged membranes, when compared to the 
membrane derived from younger donors (Del Priore and Tezel,1998; Tezel et al., 1999). 
In addition to changes in adhesion, survival and differentiation, it has been shown that the 
capacity of RPE cells to phagocytose the shed outer segment of rod photoreceptors is 
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reduced when RPE cells are seeded on aged membranes than the young membranes (Sun, et 
al., 2007). 
These functional differences are further backed up by the changes in gene expression 
between RPE cells cultured on aged and young membranes. It has been shown that the RPE 
cells seeded on aged membranes up-regulate 12 genes and downregulate 8 genes compared 
to RPE cells cultured on membranes derived from young donors suggesting the differences 
between ages are also reflected at gene level (Cai and Del Priore, 2006). 
Therefore, it is evident that there is a significant age-dependent decline in the Bruch’s 
membrane’s ability to support the RPE cell adhesion and function, and therefore RPE loss 
and dysfunction in AMD can be at least partially reflective of changes within the membrane. 
These changes in Bruch’s membrane therefore pose an obstacle for the transplanted RPE 
cells, which require fast attachment and adhesion, to survive post-transplantation. 
In addition, data from our lab and others have shown that in wet AMD, there is increased 
deposition of a glycoprotein associated with neovascularisation. This glycoprotein named 
tenascin C is deposited on the upper layer of Bruch’s membrane. Using purified tenascin C, 
we were able to show that human RPE cells lack the necessary integrins to attach to surfaces 
coated with this glycoprotein and therefore deposition of this molecule in pathological AMD 
Bruch’s membrane further reduces the chance of adhesion. Using in vitro assays we were 
able to show that if RPE cells are engineered to express a necessary receptor called 
alpha9beta1 integrin for tenascin C, they are able to attach following transplantation to the 
wet AMD derived Bruch’s membrane where as in the absence of this receptor, control RPE 
cells were unable to attach to the membrane effectively (Afshari et al 2010).  
In addition to changes mentioned above, surgical techniques used in removal of CNVs have 
been shown to damage the normal architecture of Bruch's membrane. It is well established 
that surgical removal of CNVs in the wet AMD generally leads to excision of the basement 
membrane of the Bruch’s membrane (Grossniklaus et al., 1994). Tsukahara et al using ex vivo 
models of aged Bruch’s membrane have shown that the resurfacing of the Bruch’s 
membrane is highly dependent on whether the basement membrane is intact or removed. 
The adhesion of RPE cells was much higher on aged Bruch’s membrane if the basement 
membrane was not damaged and removed (Tsukahara et al., 2002). Therefore, one of the 
limitations of the CNV removal procedure is the iatrogenic removal of the laminin rich 
basement membrane, which reduces the chance of adhesion of RPE cells transplanted 
subsequently into the subretinal space. 
In addition to the removal of the laminin rich basement membrane of Bruch’smembrane, the 
surgical procedures also lead to the exposure of deeper layers of the Bruch’s membrane. 
Various studies have assessed the adhesion rate and the survival of RPE cells on different 
layers of the Bruch’s membrane. They have revealed that RPE cell reattachment is the 
highest on the uppermost layers of the Bruch’s membrane which include basement 
membrane. As deeper layers are exposed, this adhesion rate decreases (Del Priore and Tezel, 
1998). Thus, following CNV removal, depending on which layer of the Bruch’s membrane is 
exposed , the outcome of adhesion will differ which diminishes the chances of fast and 
efficient adhesion of the RPE cells following transplantation (Del Priore and Tezel, 1998). 
RPE cells are known to attach to the human Bruch’s membrane through beta1 integrin-
mediated interaction, with extracellular ligands such as laminin, fibronectin, vitronectin and 
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collagen IV (Ho and DelPriore, 1997). Tezel et al have demonstrated that laminin and 
fibronectin supported the adhesion of RPE cells best and prevented cellular apoptosis (Tezel 
and Del Priore,1997). Since the upper most layers of the Bruch’s membrane are rich in 
laminin and fibronectin, removal of basement membrane combined with the exposure of 
deeper less adhesive substrates, limits adhesion following transplantation. 
Therefore, there is a great need for promoting cell adhesion post transplantation to allow 
resurfacing and seeding of the pathologically and surgically altered membranes. Multiple 
problems faced with transplantation therefore haves lead to more attention on 
pharmacological and less invasive techniques to halt the CNV formation. 
4.2 Photodynamic therapy and laser treatment 
Laser photocoagulation is one of the techniques that was developed to treated 
neovascularisation problem in wet AMD. Since this technique leads to full thickness retinal 
burns, this can lead to loss of visual acuity if carried out in foveal region and therefore it is 
reserved for extrafoveal CNVs. In addition, there is a high rate of recurrence of CNVs 
following treatment with this method (Vedula SS and Krzystolik M 2011). However this 
technique is effective in reducing the progression of non-subfoveal CNVs compared to 
observation alone (Virgil 2007; Verdula SS and Krzystolik M 2011). 
Photodynamic therapy on the other hand is a technique that works by injecting a 
photosensitive dye intravenously which preferentially binds to CNVs. On exposure of the 
eye to laser light, the dye can be activated leading to obliteration of the CNVs. This 
technique has the advantage of causing minimal trauma to normal choroid and membrane 
and the overlying retina. It therefore can be used for subfoveal lesions. The disadvantage 
with this technique is the necessity to repeat this procedure at least multiple times due to 
high rate of recurrence (TAP 1999;Verdula SS 2011). 
4.3 Anti-VEGF monoclonal antibodies 
One of the most recent approaches in battling wet AMD is the use of anti-VEGF monoclonal 
antibodies. Vascular endothelial growth factor has been shown to be involved in promoting 
formation of new blood vessels. The source of VEGF in AMD is believed to be the RPE cells 
themselves. Multiple studies have demonstrated presence of VEGF in RPE cells and its 
association with CNVs (Kim et al. 1999; Klifen 1997; Kvanata 1996). Although VEGF is 
necessary for neovascularisation, animal research shows that in the presence of intact 
normal Bruch’s membrane, blood vessels will not invade the subretinal area and therefore a 
pathological process must render the membrane permeable to invading growing new blood 
vessels in AMD setting (Schwesinger 2001). Regardless of this finding, use of blocking 
agents against VEGF or its receptor holds promise in halting neovascularisation. 
Animal studies have shown that blocking VEGF using different approaches can halt the 
neovascularisation process. Multiple clinical trials have assessed efficacy and safety of anti-
VEGF monoclonal antibodies which include Bevacizumab, ranibizumab, pegabtanib 
(Vendula SS and KrzystolikM 2011). A recent systematic review of randomised controlled 
trials compared recent trials using anti-VEGF in wet AMD. Pegabtanib and Ranibizumab 
were shown to be both effective in reducing the neovascularisation with improvements in 
visual acuity and quality of life (Vendula SS and Krzystolik M 2011). There are currently no 
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trials comparing these two drugs directly together. Bevacizumab, which also blocks VEGF 
and is considerably cheaper than its counterparts, has also been used off licence for treating 
wet AMD although originally it was licensed for colorectal carcinoma (Avery 2006, Emerson 
2007). Although multiple studies have shown efficacy of this monoclonal antibody in 
reducing neovascularisation, the safety profile of this antibody is not as clear as other two 
(Mitchell P 2011).  
5. Problems and challenges for future 
With increasing aging population, the number of patients with AMD is likely to rise sharply. 
The projected number of advanced AMD cases is likely to rise by 50% by year 2020 
(Friedman et al 2004). Therefore with increasing incidence of this condition, screening 
programs may be of value to allow early detection and treatment of this condition. This is of 
paramount importance as early detection has been shown to be associated with a better 
outcome and prognosis (Wong et al 2008). 
With recent advances in cell transplantation and knowledge of stem cells, it may be possible 
that stem cell derived RPE cells can be used in the treatment of AMD (Lee and Maclaren 
2011). Use of these cells may be of benefit as they have the potential to replace the lost cells 
and may not be hindered by the obstacles such as poor adhesion faced with cadaveric or 
donor derived RPE cells. For dry AMD, cell transplantation strategies are also undergoing 
clinical trials in several centres worldwide . Strategies to compare improve the survival and 
adhesion of transplanted cells to damaged Bruch's membrane are a key focus of our ongoing 
work.  
Manipulation of integrins on RPE cells or genetic engineering of transplanted cells is a new 
field that holds promise in overcoming the obstacles faced in cell transplantation. Activating 
integrins by enhancing their function or introduction of new subunits of integrins into RPE 
cells have been shown to overcome the poor attachment and integration of RPE cells over 
Bruch's membrane (Afshari et al 2010; Fang et al 2009). It is therefore possible that with 
better understanding of RPE biology, adhesion and survival of cells following 
transplantation could be improved.  
With the advent of the new therapies such as monoclonal anti-VEGF treatments, major 
advances have occurred in the treatment of wet AMD. At this point the challenges reside in 
wide access and affordable costs to allow early recognition and prevention of loss of vision 
at an early stage. Currently repeated injections of monoclonal antibodies limit their use in 
areas where access to such therapies is limited. With better understanding and experience of 
using such therapies, it is hoped that treatments with longer half lives and more affordable 
prices can be available to increasing aging population.  
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